Emerging drugs for panic disorder

Bibliography

• Westenberg HGM, Liebowitz MR. Overview of panic and social anxiety disorders. J Clin Psychiatry 2004;65(Suppl 14):22-6
   PubMed Web of Science ®Google Scholar
• Perna G. Understanding anxiety disorders: from psychology to psychopathology of defence mechanisms from threat. Riv Psichiatr; In press
   Web of Science ®Google Scholar
• Roberson-Nay R, Kendler KS. Panic disorder and its subtypes: a comprehensive analysis of panic symptom heterogeneity using epidemiological and treatment seeking samples. Psychol Med 2011; published online 18 April 2011; doi:10.1017/S0033291711000547.
   Web of Science ®Google Scholar
• Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 1993;50:306-17
   PubMed Web of Science ®Google Scholar
• Esquivel G, Schruers KR, Maddock RJ, Acids in the brain: a factor in panic? J Psychopharmacol (Oxford) 2010;24:639-47
   PubMed Web of Science ®Google Scholar
• Perna G, Caldirola D, Bellodi L. Panic disorder: from respiration to the homeostatic brain. Acta Neuropsychiatr 2004;16:57-67
   PubMed Web of Science ®Google Scholar
• Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505
   PubMed Web of Science ®Google Scholar
• Freire RC, Hallak JE, Crippa JA, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother 2011;12:1419-28
   PubMed Web of Science ®Google Scholar
• Battaglia M, Ogliari A. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev 2005;29:169-79
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2nd edition. American Psychiatric Publishing, Inc.; Washington, DC: 2009
   Google Scholar
• Van Apeldoorn FJ, van Hout WJPJ, Mersch PPA, Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand 2008;117:260-70
   PubMed Web of Science ®Google Scholar
• Yates WR. Phenomenology and epidemiology of panic disorder. Ann Clin Psychiatry 2009;21:95-102
   PubMed Web of Science ®Google Scholar
• Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. (Clinicalguideline113) National Institute for Health and Clinical Excellence. London: 2011. Available from: http://guidance.nice.org.uk/CG113 [Last accessed 21 May 2011]
   Google Scholar
• McHugh RK, Smits JAJ, Otto MW. Empirically supported treatments for panic disorder. Psychiatr Clin North Am 2009;32:593-610
   PubMed Web of Science ®Google Scholar
• Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev 2001;108:4-32
   PubMed Web of Science ®Google Scholar
• Richerson GB. Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. Nat Rev Neurosci 2004;5:449-61
   PubMed Web of Science ®Google Scholar
• Bertani A, Perna G, Arancio C, Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 1997;17:97-101
   PubMed Web of Science ®Google Scholar
• Schruers K, van Diest R, Overbeek T, Griez E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 2002;113:237-43
   PubMed Web of Science ®Google Scholar
• Schruers K, Klaassen T, Pols H, Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res 2000;93:179-87
   PubMed Web of Science ®Google Scholar
• Bailey JE. Does the brain noradrenaline network mediate the effects of the CO2 challenge? J Psychopharmacol 2003;17:252-9
   PubMed Web of Science ®Google Scholar
• Rentero N, Bruandet N, Pequignot JM, Quintin L. Catechol changes in the rat rostral ventrolateral medulla following changes in systemic CO2. Am J Physiol 1997;273:R947-55
   PubMed Web of Science ®Google Scholar
• Perna G, Bertani A, Caldirola D, Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. J Clin Psychopharmacol 2004;24:277-82
   PubMed Web of Science ®Google Scholar
• Bailey JE, Papadopoulos A, Seddon K, Nutt DJ. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. J Psychopharmacol 2009;23:117-22
   PubMed Web of Science ®Google Scholar
• Shekhar A, Keim SR, Simon JR, McBride WJ. Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 1996;55:249-56
   PubMed Web of Science ®Google Scholar
• Nardi AE, Valenca AM, Nascimento I, Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks. Psychiatry Res 2000;94:179-84
   PubMed Web of Science ®Google Scholar
• Hasler G, Nugent AC, Carlson PJ, Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry 2008;65:1166-75
   PubMed Web of Science ®Google Scholar
• Perna G, Bertani A, Caldirola D, Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol 2002;22:300-8
   PubMed Web of Science ®Google Scholar
• Bertani A, Caldirola D, Bussi R, The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol 2001;21:262-7
   PubMed Web of Science ®Google Scholar
• Perna G, Bertani A, Caldirola D, A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001;34:85-90
   PubMed Web of Science ®Google Scholar
• Pollack M, Mangano R, Entsuah R, A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007;194:233-42
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Asnis G, Mangano R, Tzanis E. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry 2009;70:550-61
   PubMed Web of Science ®Google Scholar
• Bertani A, Bellodi L, Bussi R, The effect of one-week treatment with venlafaxine on 35% CO2 hyperreactivity in patients with panic disorder: an open study. J Clin Psychopharmacol 2003;23:106-8
   PubMed Web of Science ®Google Scholar
• Bakker A, van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002;106:163-7
   PubMed Web of Science ®Google Scholar
• Perna G, Bertani A, Gabriele A, Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 1997;17:173-8
   PubMed Web of Science ®Google Scholar
• Sasson Y, Iancu I, Fux M, A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999;9:191-6
   PubMed Web of Science ®Google Scholar
• Nardi AE, Perna G. Clonazepam in the treatment of psychiatric disorders: an update. Int Clin Psychopharmacol 2006;21:131-42
   PubMed Web of Science ®Google Scholar
• Nardi AE, Valenca AM, Freire RC, Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res 2011;44:366-73
   PubMed Web of Science ®Google Scholar
• Nardi AE, Valenca AM, Nascimento I, A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Psychiatry Res 2005;137:61-70
   PubMed Web of Science ®Google Scholar
• Goddard AW, Brouette T, Almai A, Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-6
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Worthington JJ, Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003;17:276-82
   PubMed Web of Science ®Google Scholar
• Otto MW, Bruce SE, Deckersbach T. Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need. J Clin Psychiatry 2005;66(Suppl 2):34-8
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A, Calati R, Novel antidepressants and panic disorder: evidence beyond current guidelines. Neuropsychobiology 2011;63:1-7
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Desaiah D, Ossanna MJ, Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 2008;23:161-9
   PubMed Web of Science ®Google Scholar
• Mancini M, Perna G, Rossi A, Petralia A. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother 2010;11:1167-81
   PubMed Web of Science ®Google Scholar
• Cia AH, Brizuela JA, Cascardo E, Varela MF. Clonazepam and milnacipran in the treatment of patients with panic disorder and comorbid major depression. Prim Care Community Psychiatry 2006;11:51-6
   Google Scholar
• Blaya C, Seganfredo AC, Dornelles M, The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol 2007;22:153-8
   PubMed Web of Science ®Google Scholar
• De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57:19-25
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999;11:81-6
   PubMedGoogle Scholar
• Sarchiapone M, Amore M, De Risio S, Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 2003;18:35-8
   PubMed Web of Science ®Google Scholar
• Montanes-Rada F, De Lucas-Taracena MT, Sanchez-Romero S. Mirtazapine versus paroxetine in panic disorder: an open study. Int J Psychol Clin Pract 2005;9:87-93
   PubMed Web of Science ®Google Scholar
• Brunello N, Racagni G. Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol Clin Exp 1998;13:S13-19
   Web of Science ®Google Scholar
• Dannon P, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 2002;17:329-33
   PubMed Web of Science ®Google Scholar
• Seedat S, van Rheede van Oudtshoorn E, Muller JE, Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 2003;18:279-84
   PubMed Web of Science ®Google Scholar
• Bertani A, Perna G, Migliarese G, Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2004;37:206-10
   PubMed Web of Science ®Google Scholar
• Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-97
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Wright RA, Levine LR, LY354740, an mGlu2/3 receptor agonist as a novel approach to Treat Anxiety/Stress. Stress 2003;6:189-97
   PubMed Web of Science ®Google Scholar
• Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000;39:1139-46
   PubMed Web of Science ®Google Scholar
• Otto MW, Tolin DF, Simon NM, Efficacy of d-Cycloserine for enhancing response to Cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010;67:365-70
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health (NIMH). Exposure, D-Cycloserine Enhancement, and Genetic Modulators in (DCSPanic). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2008. NLM Identifier: NCT00790868 Available from: http://clinicaltrials.gov/ct2/show/NCT00790868 [Cited 22 May 2011]
   Google Scholar
• Stahl's Essential Psychopharmacology:Neuroscientific Basis & Practical Applications. 3rd edition. CUP; Cambridge: 2008
   Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66:30-40
   PubMed Web of Science ®Google Scholar
• Inoue T, Tsuchiya K, Koyama T. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav 1996;55:195-201
   PubMed Web of Science ®Google Scholar
• Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders. J Clin Psychopharmacol 2007;27:263-72
   PubMed Web of Science ®Google Scholar
• Lindner Center of HOPE, UCB, Inc.,University of Cincinnati.Levetiracetam Treatment of and Lactate-Induced Panic Attacks. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2006. NLM Identifier: NCT00279617. Available from: http://clinicaltrials.gov/ct2/show/NCT00279617 [Cited 22 May 2011]
   Google Scholar
• Grillon C, Cordova J, Levine LR, Morgan CA. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003;168:446-54
   PubMed Web of Science ®Google Scholar
• Levine L, Gaydos B, Sheehan D, Goddard A. The mGlu2/3 receptor agonist, LY354740, reduces panic anxiety induced by a CO2 challenge in patients diagnosed with panic disorder. Neuropharmacology 2002;43:294
   Web of Science ®Google Scholar
• Bergink V, Westenberg HGM. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol 2002;43:294-3
   Google Scholar
• Perkins EJ, Abraham T. Pharmacokinetics, Metabolism, and Excretion of the PepT1-Targeted Prodrug (1S, 2S, 5R, 6S)-2-[(2′S)-(2-Amino) propionyl] aminobicyclo [3.1. 0.] hexen-2,6- dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-pass Bioactivation and Dose-Linearity. Drug Metab Dispos 2007; published online 23 July 2007; doi:10.1124/dmd.107.016154
   PubMed Web of Science ®Google Scholar
• Rorick-Kehn LM, Perkins EJ, Knitowski KM, Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 2006;316:905-13
   PubMed Web of Science ®Google Scholar
• Davis M, Gendelman DS, Tischler MD, Gendelman PM. A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci 1982;2:791-805
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Rothbaum BO, Tannenbaum L, Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61:1136-44
   PubMed Web of Science ®Google Scholar
• Siegmund A, Golfels F, Finck C, D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 2011; published online 5 March 2011; doi:10.1016/j.jpsychires.2011.01.020.
   Web of Science ®Google Scholar
• Lamberty Y, Falter U, Gower AJ, Klitgaard H. Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat. Eur J Pharmacol 2003;469:97-102
   PubMed Web of Science ®Google Scholar
• Lamberty Y, Gower AJ, Klitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 2002;439:101-6
   PubMed Web of Science ®Google Scholar
• Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 2006;67:1573-6
   PubMed Web of Science ®Google Scholar
• Gorenstein EE, Kleber MS, Mohlman J, Cognitive-behavioral therapy for management of anxiety and medication taper in older adults. Am J Geriatr Psychiatry 2005;13:901-9
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:1321-5
   PubMed Web of Science ®Google Scholar
• Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005;15:69-74
   PubMed Web of Science ®Google Scholar
• Prosser JM, Yard S, Steele A, A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry 2009;9:25
   PubMedGoogle Scholar
• Sepede G, De Berardis D, Gambi F, Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 2006;26:45-9
   PubMed Web of Science ®Google Scholar
• Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 2005;21:33-40
   PubMed Web of Science ®Google Scholar
• Indiana University, AstraZeneca. A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2008. NLM Identifier: NCT00619892. Available from: http://clinicaltrials.gov/ct2/show/NCT00619892 [Cited 22 May 2011]
   Google Scholar
• VA Palo Alto Health Care System, Pfizer, University of South Florida,Lindner Center of HOPE.Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) (Pfizer Anxiety). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2008. NLM Identifier: NCT01172652. Available from: http://clinicaltrials.gov/ct2/show/NCT01172652 [Cited 22 May 2011]
   Google Scholar
• Johnson PL, Truitt W, Fitz SD, A key role for orexin in panic anxiety. Nat Med 2010;16:111-U149
   PubMed Web of Science ®Google Scholar
• Salomon RM, Ripley B, Kennedy JS, Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003;54:96-104
   PubMed Web of Science ®Google Scholar
• Nattie E. CO2, brainstem chemoreceptors and breathing. Prog Neurobiol 1999;59:299-331
   PubMed Web of Science ®Google Scholar
• Battaglia M, Bertella S, Ogliari A, Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry 2001;58:114-19
   PubMed Web of Science ®Google Scholar
• Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998;393:373-7
   PubMed Web of Science ®Google Scholar
• Meshorer E, Erb C, Gazit R, Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science 2002;295:508-12
   PubMed Web of Science ®Google Scholar
• Preter M, Klein D. Panic, suffocation false alarms, separation anxiety and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:603-12
   PubMed Web of Science ®Google Scholar
• Preter M, Lee SH, Petkova E, Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss. Psychol Med 2011;41:385-93
   PubMed Web of Science ®Google Scholar
• Borkowski AH, Barnes DC, Blanchette DR, Interaction between delta opioid receptors and benzodiazepines in CO(2)-induced respiratory responses in mice. Brain Res 2011; published online 28 April 2011; doi: 10.1016/j.brainres.2011.04.042
   PubMed Web of Science ®Google Scholar
• Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 2006;50:550-61
   PubMed Web of Science ®Google Scholar
• Choi S, Kim S, Park S, Doxapram increases corticotropin-releasing factor immunoreactivity and mRNA expression in the rat central nucleus of the amygdala. Peptides 2005;26:2246-51
   PubMed Web of Science ®Google Scholar
• Keck ME, Kern N, Erhardt A, Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1196-204
   PubMed Web of Science ®Google Scholar
• Shekhar A, Johnson PL, Fitz SD, A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. Int J Neuropsychopharmacol 2011;14:355-65
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:410-16
   PubMed Web of Science ®Google Scholar
• Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005;6:565-75
   PubMed Web of Science ®Google Scholar
• Carboni E, Wieland S, Lan N, Gee K. Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Psychopharmacology (Berl) 1996;126:173-8
   PubMed Web of Science ®Google Scholar
• Strohle A, Romeo E, di Michele F, Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003;60:161-8
   PubMed Web of Science ®Google Scholar
• Brambilla F, Mellado C, Alciati A, Plasma concentrations of anxiolytic neuroactive steroids in men with panic disorder. Psychiatry Res 2005;135:185-90
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Eser D, Romeo E, Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations. Psychoneuroendocrinology 2009;34:1586-9
   PubMed Web of Science ®Google Scholar
• Papadopoulos V, Baraldi M, Guilarte TR, Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402-9
   PubMed Web of Science ®Google Scholar
• Verleye M, Akwa Y, Liere P, The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav 2005;82:712-20
   PubMed Web of Science ®Google Scholar
• Kita A, Kohayakawa H, Kinoshita T, Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br J Pharmacol 2004;142:1059-72
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Rammes G, Eser D, Translocator Protein (18 kD) as target for Anxiolytics without benzodiazepine-like side effects. Science 2009;325:490-3
   PubMed Web of Science ®Google Scholar
• Czeh B, Fuchs E, Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 2006;15:479-86
   PubMed Web of Science ®Google Scholar
• Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in Stress-Related disorders. Curr Pharm Des 2009;15:1647-74
   PubMed Web of Science ®Google Scholar
• Kronenberg G, Berger P, Tauber R, Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 2005;38:24-9
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Yasuno F, Farris A, Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry 2009;66(1):94-7
   PubMed Web of Science ®Google Scholar
• Furmark T, Appel L, Michelgard A, Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005;58:132-42
   PubMed Web of Science ®Google Scholar
• Keller M, Montgomery S, Ball W, Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216-23
   PubMed Web of Science ®Google Scholar
• Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233-43
   PubMed Web of Science ®Google Scholar
• Hohoff C, Mullings EL, Heatherley SV, Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. J Psychiatr Res 2010;44:930-7
   PubMed Web of Science ®Google Scholar
• Lopes LV, Sebastiao AM, Ribeiro JA. Adenosine and Related Drugs in Brain Diseases: present and future in clinical trials. Curr Top Med Chem 2011;11:1087-101
   PubMed Web of Science ®Google Scholar
• Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51
   PubMed Web of Science ®Google Scholar
• Zohar J, Dannon P, Sasson Y, Pindolol augmentation in treatment-resistant panic disorder and obsessive–compulsive disorder. Eur Neuropsychopharmacol 1998;8:S99
   Google Scholar
• Hirschmann S, Dannon PN, Iancu I, Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-9
   PubMed Web of Science ®Google Scholar
• Van Vliet I, Westenberg H, Boer den J. Pindolol does not augment the panicolytic effects of fluvoxamine in panic disorders patients. Eur Neuropsychopharmacol 1998;8:S257-8
   Google Scholar
• Sela VR, Biesdorf C, Ramos DH, Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze. Neurosci Lett 2011;495:63-6
   PubMed Web of Science ®Google Scholar
• Freire RC, Perna G, Nardi AE. Panic disorder respiratory subtype: psychopathology, laboratory challenge tests, and response to treatment. Harv Rev Psychiatry 2010;18:220-9
   PubMed Web of Science ®Google Scholar
• Caldirola D, Teggi R, Bondi S, Lopes F. Is there a hypersensitive visual alarm system in panic disorder? Psychiatry Res 2011;187:387-91
   PubMed Web of Science ®Google Scholar
• Yeragani VK, Rao R, Tancer M, Uhde T. Paroxetine decreases respiratory irregularity of linear and nonlinear measures of respiration in patients with panic disorder. A preliminary report. Neuropsychobiology 2004;49:53-7
   PubMed Web of Science ®Google Scholar
• Perna G, Alpini D, Caldirola D, Serotonergic modulation of the balance system in panic disorder: an open study. Depress Anxiety 2003;17:101-6
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Fyer AJ, Gorman JM, Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry 1984;41:764-70
   PubMed Web of Science ®Google Scholar
• Gorman JM, Askanazi J, Liebowitz MR, Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 1984;141:857-61
   PubMed Web of Science ®Google Scholar
• D'Amato FR, Zanettini C, Lampis V, Unstable maternal environment, separation anxiety, and heightened CO2 sensitivity induced by gene-by-environment interplay. PLoS ONE 2011;6(4):e18637
   PubMed Web of Science ®Google Scholar
• Johnson PL, Shekhar A. Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors. J Neurosci 2006;26:7093-104
   PubMed Web of Science ®Google Scholar
• Lim LW, Blokland A, Tan S, Attenuation of fear-like response by escitalopram treatment after electrical stimulation of the midbrain dorsolateral periaqueductal gray. Exp Neurol 2010;226:293-300
   PubMed Web of Science ®Google Scholar